The safety labeling for the beta interferons that are used to treat multiple sclerosis have been updated to include warnings about injection site reactions.
Formulary Watch
Latest News
All News
Advertisement
Previously, the FDA had issued an EUA for those over the age of 65 and those at high risk for severe COVID-19 or exposure to the virus.
Half of the step therapy protocols for specialty drugs evaluated by investigators go beyond what is suggested in treatment guidelines.
Eprontia is the first liquid formulation of topiramate approved to both treat and prevent seizure.
Paxlovid, an at-home treatment for COVID-19, reduces illness severity, hospitalizations, and deaths among adults by 89%.
CVS Caremark has removed 10 branded products from its formulary and added about 30 additional products.
The studies conducted to support Verzenio’s most recent approval for the treatment of high-risk early breast cancer provided additional safety data.
The FDA didn’t have enough data to assess the risks and benefits of Zyesami.
The antidepressant fluvoxamine reduced the need for hospitalization in high-risk patients, according to a new study.
Advertisement
UK regulatory authorities approved molnupiravir to treat patients with mild-to-moderate COVID-19.
This Tufts study has found that plans that restrict orphan drugs do so by narrowing the patient population who can receive them.
Prime’s formularies will include the insulin biosimilar over the reference product Lantus beginning in January 2022.
The agency needs more time to review new information on the analytical method used.
Several generics of the cancer therapeutic are available.
But groups such as Doctors Without Borders say the agreement with the Medicines Patent Pool excludes key manufacturing countries.
EmsanaRx, the new PBM, aims to provide large employers with flexibility and transparency on drug spending.
Vuity, developed by Allergan, is a once-daily eye drop to treat presbyopia.
Novartis’ Scemblix was approved for previously treated patients and for those who are resistant to TKI inhibitors.
The dose is one-third of the dose given to people 12 years and older.
Some have expressed concerns about the risk of myocarditis and unknown longer-term side effects.
Dexamethasone is recommended by the NIH and the World Health Organization for treating COVID-19.
Specialty drug prices are rising as these therapeutics replace lower-cost therapies.
Novatis is seeking approval for Kymriah in adult patients with advanced follicular lymphoma.
The phase 2/3 trial showed a favorable safety profile, robust immune responses and a vaccine efficacy rate of 90.7% in children 5 to 11 years of age.
Advertisement
Advertisement